Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha
about
Serum albumin and body weight as biomarkers for the antemortem identification of bone and gastrointestinal disease in the common marmosetInflammatory bowel diseaseOn the role of tumor necrosis factor and receptors in models of multiorgan failure, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.The function of tumour necrosis factor and receptors in models of multi-organ inflammation, rheumatoid arthritis, multiple sclerosis and inflammatory bowel disease.Review article: efficacy of infliximab in Crohn's disease--induction and maintenance of remission.Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease.Integrating anti-tumor necrosis factor therapy in inflammatory bowel disease: current and future perspectives.Infliximab: the evidence for its place in therapy in ulcerative colitis.Infliximab and ulcerative colitis.Animal models of colitis-associated carcinogenesis.A critical assessment of new therapies in inflammatory bowel disease.Infliximab in moderately severe glucocorticoid resistant ulcerative colitis: a randomised controlled trial.Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.Systematic review: Infliximab therapy in ulcerative colitis.The role of TNFalpha in ulcerative colitis.CBLB502 administration protects gut mucosal tissue in ulcerative colitis by inhibiting inflammation.Effects of the macrolide drug tylosin on chronic diarrhea in rhesus macaques (Macaca mulatta).Efficacy of biological therapies in inflammatory bowel disease: systematic review and meta-analysis.Opportunistic infections with anti-tumor necrosis factor-α therapy in inflammatory bowel disease: meta-analysis of randomized controlled trials.Novel intestinal Helicobacter species isolated from cotton-top tamarins (Saguinus oedipus) with chronic colitis.TNF-alpha potentiates the ion secretion induced by muscarinic receptor activation in HT29cl.19A cells.Infliximab in ulcerative colitis.PLD pathway involved in carbachol-induced Cl- secretion: possible role of TNF-alpha.Is infliximab effective for induction of remission in patients with ulcerative colitis?Infliximab for refractory ulcerative colitis or indeterminate colitis: an open-label multicentre study.The role of cytokine gene polymorphisms in determining disease susceptibility and phenotype in inflammatory bowel disease.The role of the tumor necrosis factor receptor in 2,4,6-trinitrobenzene sulfonic acid (TNBS)-induced colitis in mice.Combination therapy of pentoxifylline and TNFalpha monoclonal antibody in dextran sulphate-induced mouse colitis.
P2860
Q27342432-63AC010F-4A10-405A-A769-17F4987820C2Q29615500-ADB7A55C-62D5-4479-9A57-D8D4417C1050Q33333935-236E47EE-DA79-4148-9581-71AB24A08F4AQ33782327-1F55D978-1A70-45E8-9B64-139BD9C899DEQ33793926-7A0A2488-952E-4E7F-8F70-F50D5351CB36Q34127277-3C9B73F4-EBC5-4D51-868B-8BB98EB59259Q34316206-C50EF66C-68F7-4545-8152-A2253FA64FEEQ34449876-2334E883-88AD-4DD9-B468-F51778910EE6Q34503548-2F29AC91-887F-4B53-BCA1-C7D8238E4734Q34512820-729EAFEB-2CD0-45B4-B8BD-EDD937C59D24Q34631399-A7E7670C-AA1C-4273-A337-842A7E5258E0Q35595821-D061CE3F-67AF-4D6E-AFE0-D9DA9B4D8F3AQ36656427-3205DED1-6337-4A21-9500-31B3DE8F5488Q36710327-5AE4FEE3-6EDE-4880-B9B0-36249CE90B3DQ36849148-B9560C12-8234-47DA-9157-A3EE6A761E18Q37227202-0A04E0A7-FFBE-44C6-973D-6A746BF358B4Q37243876-33AE6299-DBCF-4F0A-AC9C-CFFA1ABF71A2Q37853359-0168E104-E44E-4547-99C9-377CEE4AFE32Q38104612-BE9C21EE-D005-4595-854D-B89020D85DD5Q39445803-13E7A04D-234A-48EB-B9A9-81B9B8B2A9C9Q40894653-5B17E2E4-438E-4445-8CF0-10732BB5A6DEQ41860347-E291FC34-BC63-4DAA-9C04-49E8E88F8E3AQ43540333-A832B232-22A0-4D56-8B82-DBF1A0342195Q43624352-0FB68FBD-FD89-4786-9893-AA1FAEB1A78DQ44517208-2A68DD39-6518-422C-B38D-AFE65C0E6883Q44539365-EF359FFA-3191-43DF-BC78-9370FFC55C14Q46679822-470EE333-ED4F-4C78-82B4-64B24787DC7FQ53934663-145C5454-512F-40D3-A44A-684DF1424ADC
P2860
Treatment of ulcerative colitis in the cottontop tamarin using antibody to tumour necrosis factor alpha
description
1997 nî lūn-bûn
@nan
1997 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
1997 թվականի մայիսին հրատարակված գիտական հոդված
@hy
1997年の論文
@ja
1997年論文
@yue
1997年論文
@zh-hant
1997年論文
@zh-hk
1997年論文
@zh-mo
1997年論文
@zh-tw
1997年论文
@wuu
name
Treatment of ulcerative coliti ...... o tumour necrosis factor alpha
@ast
Treatment of ulcerative coliti ...... o tumour necrosis factor alpha
@en
type
label
Treatment of ulcerative coliti ...... o tumour necrosis factor alpha
@ast
Treatment of ulcerative coliti ...... o tumour necrosis factor alpha
@en
prefLabel
Treatment of ulcerative coliti ...... o tumour necrosis factor alpha
@ast
Treatment of ulcerative coliti ...... o tumour necrosis factor alpha
@en
P2093
P2860
P356
P1433
P1476
Treatment of ulcerative coliti ...... o tumour necrosis factor alpha
@en
P2093
P2860
P304
P356
10.1136/GUT.40.5.628
P407
P577
1997-05-01T00:00:00Z